why choose us

Clinical Trials Search

Showing 11,400 of 132,963 result(s)
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1;2 Mutations

Status: COMPLETED

Condition: Breast Cancer

Interventions: The starting dose of axitinib is 5 mg twice daily by mouth with meals.
(reception is desirable at the same time every day)

Date: 2023-06-06

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic HCV

Status: COMPLETED

Condition: Chronic Hepatitis C Virus

Interventions: 550 mg administered orally once a day (QD) for 8 weeks

Date: 2023-06-06

NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients

Status: COMPLETED

Condition: Breast Cancer

Interventions: Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radioth

Date: 2023-06-06

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Status: COMPLETED

Condition: Glioblastoma

Interventions: CVGBM will be administered as an IM injection.

Date: 2023-06-06

Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population

Status: COMPLETED

Condition: Local Anesthetic

Interventions: ocular surface anesthesia

Date: 2023-06-06

HER2 and LA;mUC: A Multi-country Chart Review Cohort Study

Status: COMPLETED

Condition: Urothelial Carcinoma

Interventions:

Date: 2023-06-05

Financial Support in an Underserved and Low-Income Population With Heart Failure

Status: Completed

Condition: Heart Failure, Systolic

Interventions: A debit card will be loaded with $500 and can be used like a typical debit card.

Date: 2023-06-05

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

Status: COMPLETED

Condition: Smallpox

Interventions: 100 mg tablet of Form H and 100 mg tablet of Form II

Date: 2023-06-05

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Status: Completed

Condition: Obesity

Interventions: single dose of active drug

Date: 2023-06-05

POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis

Status: Completed

Condition: Atopic Dermatitis

Interventions: Patients in monotherapy cohorts will be treated with BSI-045B.

Date: 2023-06-05